DZnep is sometimes erroneously considered to be a histone methyltransferase EZH2 inhibitor, because of the misinterpretation of a report showing that it inhibits histone methylation sites targeted by EZH2 in cancer cells21. The gene discussed is EZH2; the disease is cancer.